LAST CHANCE TO SAVE! New Trends for Life Sciences at PACK EXPO Southeast
Discover all the latest packaging solutions for life sciences products at the all-new PACK EXPO Southeast in Atlanta, GA, March 10-12, 2025
REGISTER ASAP FOR $30!

FDA MedWatch - Heparin: Drug Safety Communication - Important change to Heparin container labels to clearly state the total drug strength

Heparin: Drug Safety Communication - Important change to heparin container labels to clearly state the total drug strength

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

AUDIENCE: Health Professionals, Patients, Home Care

ISSUE: FDA is notifying health care professionals, caregivers, and patients about a change to the container and carton labels for heparin products.

This label change will require manufacturers of Heparin Lock Flush Solution, USP and Heparin Sodium Injection, USP to clearly state the strength of the entire container of the medication followed by how much of the medication is in 1 milliliter (mL). These modifications will eliminate the need for health care professionals to calculate the total amount of heparin medication in a product containing more than 1 mL, thereby reducing the risk of miscalculations that may result in medication errors.

BACKGROUND: Heparin is used to prevent blood clots from forming in people who have certain medical conditions or who are undergoing certain medical procedures that may increase the chance that clots will form, or to stop the growth of clots that have already formed in the blood vessels and to prevent blood clots from forming in catheters that are left in veins over a period of time.

RECOMMENDATION: Health care professionals, caregivers, and patients should be aware that that there will be a transition period before and after the official implementation date on May 1, 2013, during which both the current heparin container labels and the revised heparin container labels will be available in the marketplace. To minimize the potential for medication errors, users should consider separating the supplies of “current” and “revised” labeled heparin, and use all of the supplies of the “current” heparin before using products with the “revised” container label.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.

LAST CHANCE TO SAVE! New Tech for Life Sciences at PACK EXPO Southeast
The exciting new PACK EXPO Southeast 2025 unites all vertical markets in one dynamic hub, generating more innovative answers to packaging challenges for life sciences products. Don’t miss this extraordinary opportunity for your business!
REGISTER ASAP FOR $30!
LAST CHANCE TO SAVE! New Tech for Life Sciences at PACK EXPO Southeast